Literature DB >> 6119787

Clinical and endocrine aspects of treatment with ranitidine.

E J Boyd, N R Peden, M C Browning, J H Saunders, K G Wormsley.   

Abstract

Ranitidine has been shown to heal the majority of duodenal ulcers during treatment with 300 or 320 mg daily for 4 to 8 weeks. Twice-daily dosage improved compliance. Subsequent maintenance treatment with ranitidinie, 150 mg at night prevented relapse in the majority of patients during 6-months' follow-up. Ranitidine did not appear to have any anti-androgenic effects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6119787

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Effect of a new potent H2-receptor antagonist on meal-stimulated gastric acid secretion and serum gastrin concentration in duodenal ulcer patients.

Authors:  S Brozinsky; D L Hogan; J I Isenberg; C T Richardson
Journal:  Dig Dis Sci       Date:  1984-02       Impact factor: 3.199

4.  Ranitidine and testosterone secretion in man.

Authors:  V Savarino; M Giusti; C Mansi; M Marugo; G Delitala; G Celle
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

Review 5.  Drugs for the prevention of peptic ulcer recurrence.

Authors:  D W Piper
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

6.  The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders.

Authors:  M L McFadyen; P I Folb; R Miller; I N Marks; M G Moshal
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 8.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.